Patents Examined by Anthony Caputa
-
Patent number: 7122375Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.Type: GrantFiled: October 24, 2001Date of Patent: October 17, 2006Assignee: Genentech, Inc.Inventors: Audrey Goddard, Paul J. Godowski, Austin L. Gurney, Margaret Ann Roy, William I. Wood
-
Patent number: 7112657Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.Type: GrantFiled: October 19, 2001Date of Patent: September 26, 2006Assignee: Genentech, Inc.Inventors: Audrey Goddard, Paul J. Godowski, Austin L. Gurney, James Pan, William I. Wood
-
Patent number: 6908619Abstract: The CAMP factor gene of Streptococcus uberis (S. uberis) is described, as well as the recombinant production of CAMP factor therefrom. CAMP factors can be used in vaccine compositions for the prevention and treatment of bacterial infections.Type: GrantFiled: January 21, 1999Date of Patent: June 21, 2005Assignee: University of SaskatchewanInventors: Min Jiang, Andrew A. Potter, Philip Ronald MacLachlan
-
Patent number: 6436411Abstract: Treatment of tumors, including their metastases, is described. Retrieved cytokines and other molecules from the growth medium of human monocytes stimulated ex vivo with gamma globulin, or other immune stimulators are employed for cancer therapy.Type: GrantFiled: October 23, 2000Date of Patent: August 20, 2002Assignee: The Center for the Improvement of Human Functioning, Int'l., Inc.Inventors: Neil H. Riordan, Hugh D. Riordan
-
Patent number: 6372490Abstract: Disclosed are complexes of the MDM2 protein and a novel MDM2-interacting protein (MDMIP). Also disclosed are nucleic acids encoding the MDMIP polypeptide, as well as derivatives, fragments, analogs and homologs of the MDMIP polypeptide and MDM2-MDMIP complexes.Type: GrantFiled: February 22, 2000Date of Patent: April 16, 2002Assignee: CuraGen CorporationInventors: Krishnan Nandabalan, Meijia Yang, Vincent Schulz
-
Patent number: 6277828Abstract: Stable, aqueous pharmaceutical formulations of human nerve growth factor (NGF) in aqueous isotonic solutions, buffered to maintain the pH from about 4.5 to about 6.0, and optionally containing a carrier such as human serum albumin are provided. Also provided are aqueous NGF formulations suitable for lyophilization and subsequent reconstitution in which rhNGF is admixed with sugars, optionally HSA, and buffer. The formulations are useful for the treatment of Alzheimer's disease and other neuronal disorders.Type: GrantFiled: August 20, 1993Date of Patent: August 21, 2001Assignee: Syntex (U.S.A.) Inc.Inventors: Victoria M. Knepp, Deborah M. Lidgate, Richard Maskiewicz, Leo Gu
-
Patent number: 6242570Abstract: The invention relates to novel recombinant fusion proteins comprising two or more erythropoietin molecules. The fusion proteins can be linked by a peptide linker. The fusion proteins can be used, for example, to treat or prevent anemia in a mammal. Also disclosed are nucleotide sequences encoding the fusion proteins vectors comprising the nucleic acid sequences of the fusion proteins and host cells transfected with the vectors.Type: GrantFiled: July 10, 1997Date of Patent: June 5, 2001Assignee: Beth Israel Deaconess Medical CenterInventor: Arthur J. Sytkowski
-
Patent number: 6143519Abstract: A human endothelin-bombesin receptor polypeptide and DNA (RNA) encoding such polypeptide and a procedure for producing such polypeptide by recombinant techniques is disclosed. Also disclosed are methods for utilizing such polypeptide for identifying agonists and antagonists to such polypeptide. Agonists to the endothelin-bombesin receptor polypeptide of the present invention may be used to treat asthma, Parkinson's Disease, acute heart failure, hypotension and osteoporosis. Antagonists against such polypeptides may be used therapeutically to treat hypertension, ulcerigenesis, subarachnoid hemorrhage, asthma, tumors, ciclosporin toxicity, cancer and septic shock. Also disclosed are diagnostic methods for detecting mutations in the polynucleotides of the present invention and for detecting levels of the soluble polypeptides in samples derived from a host.Type: GrantFiled: February 26, 1998Date of Patent: November 7, 2000Assignee: Human Genome Sciences, Inc.Inventors: Yi Li, Craig A. Rosen, Chandrika Kumar
-
Patent number: 5891997Abstract: A novel polypeptide functions as the .beta. chain of an oncostatin M receptor and is thus designated OSM-R.beta.. Heterodimeric receptor proteins comprising OSM-R.beta. and gp130 bind oncostatin M and find use in inhibiting biological activities mediated by oncostatin M.Type: GrantFiled: April 10, 1998Date of Patent: April 6, 1999Assignee: Immunex CorporationInventors: Bruce Mosley, David J. Cosman
-
Patent number: 5518724Abstract: A new virus not neutralized or bound by monoclonal antibodies which are group neutralizing to all IBDV vaccines of current art, and capable of inducing infectious bursal disease in poultry is identified, in essentially pure form. A test kit, and assay for the presence of the virus is disclosed, together with the vaccine incorporating the virus. A monoclonal antibody Mab 50, which neutralizes the virus, form the basis of an alternative vaccine.Type: GrantFiled: September 15, 1992Date of Patent: May 21, 1996Assignee: University of MarylandInventors: David B. Snyder, deceased, Vikram Vakharia
-
Patent number: 5500366Abstract: T-cell epitopes of or derived from the TraT protein of E. coli have been identified and used in the preparation of complexes with immunogens to enhance or provide immune responses to the immunogens. The complexes can be prepared directly, by chemical linkage, or as fusion proteins. In the latter context, polynucleotides encode a fusion protein which a transformed host can express. The fusion proteins may be expressed intracellularly or exported to and expressed on the surface of the transformant host.Type: GrantFiled: March 16, 1993Date of Patent: March 19, 1996Assignee: Biotech Australia Pty. Ltd.Inventors: Gregory J. Russell-Jones, Andrew F. Geczy